DelistingOct 1, 2026, 04:06 PM
Lantern Pharma Faces Nasdaq Delisting Warning Over Low Market Value
AI Summary
Lantern Pharma Inc. has received a notice from Nasdaq indicating non-compliance with continued listing standards. The company's market value of listed securities has fallen below the $35 million minimum for 30 consecutive business days, and it also fails to meet other listing requirements. Lantern Pharma has 180 days, until March 24, 2027, to regain compliance by ensuring its market value of listed securities closes at or above $35 million for at least 10 consecutive business days. Failure to do so could result in delisting from the Nasdaq Capital Market.
Key Highlights
- Lantern Pharma Inc. received notice from Nasdaq for non-compliance with Listing Rule 5550(b)(2).
- The company's market value of listed securities has been below the $35,000,000 minimum for 30 consecutive business days.
- Lantern Pharma also does not meet requirements under Listing Rules 5550(b)(1) and 5550(b)(3).
- The company has 180 days, until March 24, 2027, to regain compliance.
- To regain compliance, market value of listed securities must close at $35,000,000 or more for 10 consecutive business days.
Price Impact
More from LTRN